Early ocrevus treatment may tame MS brain inflammation, small study hints
NCT ID NCT04466150
First seen Jan 26, 2026 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This study gives ocrelizumab (Ocrevus) to 30 people newly diagnosed with relapsing multiple sclerosis or a first high-risk attack. Researchers measure spinal fluid markers of inflammation before and after 3 years of treatment to see if the drug reduces chronic brain inflammation. The goal is to understand if early treatment can better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California San Francisco
San Francisco, California, 94158, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab (Ocrevus)
What this could lead to
If successful, this could show that starting ocrelizumab early in MS helps control chronic brain inflammation, potentially slowing disease progression.
What could go wrong
This is a small, early-phase study with only 30 participants and no placebo group. Results may not apply to all MS patients, and ocrelizumab carries risks like infusion reactions and increased infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.